Not Signed In - ISTA Pharmaceuticals Announces Positive Preliminary Xibrom(TM) Once-daily Formulation Clinical Results From U.S. Phase III Trials
Fri, 09 Feb 2007 08:00 AM EST
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced highly statistically significant results from its initial analysis of the Company's U.S. Phase III clinical trials of Xibrom(TM) (bromfenac sodium ophthalmic solution) once-daily formulation. The multi-center studies evaluated Xibrom once-daily formulation versus placebo in over 500 patients who underwent cataract surgery. [click link for full article] ...
Related Topics
- Clinical Trials
- Antithrombin III
- Pharmacology
- Psychopharmacology
- Familial Dysautonomia
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Clinical Growth Charts
- Tb
- Brain injury that results in physical, emotional, or intellectual changes or deficits
- Daily Supplements
- Congenital antithrombin III deficiency
- Pediatric Aids
- Daily Supplement Dosages
- Daily Bladder Diary
- Cranial mononeuropathy III - diabetic type
- Cranial mononeuropathy III - compression type
- Headaches that interfere with daily activities
- Antithrombin
- AIDS - Living and Coping
email this page
print this page
bookmark this page
feedback on this page
